Buradasınız

Anasayfa » Content

PRIMER GLOMERÜLONEFRITLI OLGULARıMıZıN ÖZELLİKLERİ

FEATURES OF OUR PATIENTS WITH PRIMARY GLOMERULONEPHRITIS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2001

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The distribution of the types of primary glomerulonephritis (GN) varies from one center to another depending on ethnicity, geographical region and the indication for biopsy. It was observed that the most frequent diagnoses reached at 'our center in the last decade when the biopsy results of 283 patients (159 males, 124 females, mean age: 32.9±W, range: 15-70) diagnosed as primary GN were: membranoproliferative glomerulonephritis (MPGN) (26.6%), membranous glomerulonephritis (MGN) (23.4%) and diffuse proliferative glomerulonephritis (DPGN) (20.9%). Of the biopsied cases, 39.2% had pure nephrotic syndrome, 30.4% nephrotic+nephritic syndrome, and 25.1% nephritic syndrome. Also, 5.3% of the cases were biopsied because of asymptomatic urinary abnormalities. The most frequent diagnoses in nephrotic syndrome, nephritic syndrome, nephrotic+nephritic syndrome, and in patients.with asymptomatic urinary abnormalities were, respectively, MPGN (29.4%), DPGN (29.6%), MPGN (32.6%), and DPGN (33.3%). It is known that MPGN -the pathogenesis of which is associated with an immune-complex mechanism- has been declining in developed countries; and this condition can be explained with the decrease in infections. Although we excluded known secondary causes in our study, finding a high prevalence of MPGN might make us think that undefined infective agents still play important roles in the pathogenesis ofGN in our country.
Bookmark/Search this post with
Abstract (Original Language): 
Primer glomerülonefrit (GN) tiplerinin dağılımı ırk, coğrafi bölge ve biyopsi endikasyonuna göre merkezden merkeze değişmektedir. Merkezimizde son 10 yıllık dönemde primer GN tanısı alan 283 (159 erkek, 124 kadın, yaş ortalaması: 32.9±10, sınırlar: 15¬70) olgunun biyopsi sonuçlarının dağılımını incelediğimiz çalışmamızda en sık konulan tanıların: membranoproliferatif glomerülonefrit (MPGN) (% 26.6), membranöz glomerülonefrit (MGN) (%23.4) ve dijfüz proliferatif glomerülonefrit (DPGN) (%20.9) olduğu gözlendi. Biyopsi yapılan olguların %39.2 'sinde saf nefrotik sendrom, %30.4'ünde nefrotik+nefritik sendrom, %25.1 'inde ise nefritik sendrom kliniği gözlendi. Ayrıca olguların %5.3 'üne de asemptomatik idrar analizi bozukluğu nedeni ile biyopsi yapılmıştı. Nefrotik sendromlularda MPGN (%29.4), nefritik sendromlularda DPGN (%29.6), nefrotik+nefritik sendromlularda MPGN(%32.6) ve asemptomatik idrar analizi bozukluğu olanlarda ise DPGN (%33.3) en sık konulan tanılardı. Patogenezinde immun kompleks ile ilişkili mekanizmanın öngörüldüğü MPGN'nin gelişmiş ülkelerde son yıllarda önemli oranda gerilediği, bu durumun da enfeksiyonlardaki azalmayla açıklandığı bilinmektedir. Çalışmada bilinen sekonder nedenleri dışlamamıza karşın, MPGN'nin yüksek oranda bulunması ülkemiz şartlarında tanımlanamayan enfektif ajanların GN patogenezinde halen önemli rol oynadığını düşündürmektedir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_363.pdf
  • 4
249-253
  • Turkish

REFERENCES

References: 

1. Vollmer WM, Wahl PW, Blagg CR. Survival with dialysis and transplantation in patients with end-stage renal disease. N Eng J Med 1983;308:1553-8.
2. Disney AP, Correll RL. Report of the Australian and New Zeland combined dialysis and transplant registry. MedJAust 1981;1:117-122.
3.
Tür
k Nefroloji Derneği. Türkiye'de Nefroloji-Dializ ve Transplantasyon. Erek R, Süleymanlar G, Serdengeçti K (ed). Türk Nefroloji Derneği Yayınları, İstanbul 2000, sayfa 7-12.
4. Guidelines Subcommittee of the World Health Organization-International Society of Hypertension
(WHO-ISH). 1999 World Health Organization-
International Society of Hypertension guidelines for the management of hypertension. J Hypertension 1999;17:151-83.
5. Nunez JFM, Cameron JS. Renal function and disease in the elderly. London, Butterworths, 1987.
6. Orofino L, Quereda C, Lamas S, et al. Hypertension in primary chronic glomerulonephritis: analysis of 288 biopsied patients. Nephron 1987;45:22-6.
7. Kheder MA, Ben Maiz H, Abderrahim E, et al. Hypertension in primary chronic glomerulonephritis
analysis of 359 cases. Nephron 1993;63:140-4.
8. Modesto-Segonds A, Ah-Soune MF, Durand D, Sue JM. Renal biopsy in the elderly. Am J Nephrol 1993;13:27-34.
9. Mitwalli AH, Al Wakeel JS, Al Mohaya SS, et al.
Pattern of glomerular disease in Saudia Arabia. Am J
Kidney Dis 1996;27:797-802.
10. Schena FP. Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. Italian Group of Renal Immunopathology. Nephrol Dial Transplant 1997;12:418-26.
11. Yahya TM, Pingle A, Boobes Y, Pingle S. Analysis of 490 kidney biopsies: Data from the United Arab Emirates Renal Diseases Registry. J Nephrol 1998;11:148-50.
12. Abrass CK. Glomerulonephritis in the elderly. Am J
Nephrol 1985;5:409-18.
13. Di Belgiojoso GB, Ferrario F. Membranoproliferative glomerulonephritis. In: Massry SG, Glassock RJ (eds). Glomerular Diseases. Textbook of Nephrology. Williams and Wilkins, Baltimore, Maryland, 1995, pp 681-771.
14. Gonzalo A, Matesanz R, Teruel JL, Ortuno J. Incidence of membranoproliferative glomerulonephritis in a Spanish population. Clin Nephrol 1986;26:161.
15. Jungers P, Forget D, Droz D, Noel LH, Grunfeld JP.
Membranoproliferative glomerulonephritis (MPGN) is disappearing in France: Epidemiologic data on 1231 patients with primary chronic glomerulonephritis
(abstract). Kidney Int 1985;27:829-30.
16. Donadio JV. Membranoproliferative glomerulonephritis. In: Schrier RW, Gottschalk CW (eds). Diseases of the Kidney. Little, Brown and
Company, Boston, 1993, pp 1815-38.
17. Fearon DT, Daha MR, Strom TB, Weiler JM, Carpenter CB, Austen KF. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection. Transplant Proc 1977;9:729-39.
18. Ooi YM, Vallota EH, West CD. Classical complement
1 pathway activation in membranoproliferative glomerulonephritis. Kidney Int 1976;9:46-53.
19. Davis CA, Marder H, West CD. Circulating immune complexes in membranoproliferative glomerulonehritis.
Kidney Int 1981;20:728-32.
20. Soiling J. Circulating immune complexes in glomerulonephritis: a longitudinal study. Clin Nephrol 1983;20:177-89.
253

Thank you for copying data from http://www.arastirmax.com